GR3027	O
antagonizes	O
GABAA	B-GP
receptor	I-GP
-	O
potentiating	O
neurosteroids	O
and	O
restores	O
spatial	O
learning	O
and	O
motor	O
coordination	O
in	O
rats	B-OG
with	O
chronic	O
hyperammonemia	B-DS
and	O
hepatic	B-DS
encephalopathy	I-DS

M	O
.	O

Johansson	O
and	O
A	O
.	O

Agusti	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Hepatic	B-DS
encephalopathy	I-DS
(	O
HE	B-DS
)	O
is	O
one	O
of	O
the	O
primary	O
complications	O
of	O
liver	B-DS
cirrhosis	I-DS
.	O

Current	O
treatments	O
for	O
HE	B-DS
,	O
mainly	O
directed	O
to	O
reduction	O
of	O
ammonia	O
levels	O
,	O
are	O
not	O
effective	O
enough	O
because	O
they	O
cannot	O
completely	O
eliminate	O
hyperammonemia	B-DS
and	O
inflammation	O
,	O
which	O
induce	O
the	O
neurological	O
alterations	O
.	O

Studies	O
in	O
animal	B-OG
models	O
show	O
that	O
overactivation	O
of	O
GABAA	B-GP
receptors	I-GP
is	O
involved	O
in	O
cognitive	O
and	O
motor	O
impairment	O
in	O
HE	B-DS
and	O
that	O
reducing	O
this	O
activation	O
restores	O
these	O
functions	O
.	O

We	O
have	O
developed	O
a	O
new	O
compound	O
,	O
GR3027	O
,	O
that	O
selectively	O
antagonizes	O
the	O
enhanced	O
activation	O
of	O
GABAA	B-GP
receptors	I-GP
by	O
neurosteroids	O
such	O
as	O
allopregnanolone	O
and	O
3α	O
,	O
21	O
-	O
dihydroxy	O
-	O
5α	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
(	O
THDOC	O
).	O

This	O
work	O
aimed	O
to	O
assess	O
whether	O
GR3027	O
improves	O
motor	O
incoordination	O
,	O
spatial	O
learning	O
,	O
and	O
circadian	O
rhythms	O
of	O
activity	O
in	O
rats	B-OG
with	O
HE	B-DS
.	O

GR3027	O
was	O
administered	O
subcutaneously	O
to	O
two	O
main	O
models	O
of	O
HE	B-DS
:	O
rats	B-OG
with	O
chronic	O
hyperammonemia	B-DS
due	O
to	O
ammonia	O
feeding	O
and	O
rats	B-OG
with	O
portacaval	O
shunts	O
(	O
PCS	O
).	O

Motor	O
coordination	O
was	O
assessed	O
in	O
beam	O
walking	O
and	O
spatial	O
learning	O
and	O
memory	O
in	O
the	O
Morris	O
water	O
maze	O
and	O
the	O
radial	O
maze	O
.	O

Circadian	O
rhythms	O
of	O
ambulatory	O
and	O
vertical	O
activity	O
were	O
also	O
assessed	O
.	O

In	O
both	O
hyperammonemic	O
and	O
PCS	O
rats	B-OG
,	O
GR3027	O
restores	O
motor	O
coordination	O
,	O
spatial	O
memory	O
in	O
the	O
Morris	O
water	O
maze	O
,	O
and	O
spatial	O
learning	O
in	O
the	O
radial	O
maze	O
.	O

GR3027	O
also	O
partially	O
restores	O
circadian	O
rhythms	O
of	O
ambulatory	O
and	O
vertical	O
activity	O
in	O
PCS	O
rats	B-OG
.	O

GR3027	O
is	O
a	O
novel	O
approach	O
to	O
treatment	O
of	O
HE	B-DS
that	O
would	O
normalize	O
neurological	O
functions	O
altered	O
because	O
of	O
enhanced	O
GABAergic	O
tone	O
,	O
affording	O
more	O
complete	O
normalization	O
of	O
cognitive	O
and	O
motor	O
function	O
than	O
current	O
treatments	O
for	O
HE	B-DS
.	O

several	O
million	O
patients	O
with	O
liver	B-DS
cirrhosis	I-DS
suffer	O
from	O
minimal	B-DS
hepatic	I-DS
encephalopathy	I-DS
(	O
MHE	B-DS
)	O
with	O
psychomotor	O
slowing	O
,	O
attention	O
deficits	O
,	O
mild	O
cognitive	O
impairment	O
,	O
and	O
impaired	O
visuomotor	O
coordination	O
(	O
13	O
,	O
22	O
,	O
44	O
).	O

These	O
neurological	O
alterations	O
reduce	O
the	O
patient	O
'	O
s	O
quality	O
of	O
life	O
and	O
ability	O
to	O
perform	O
daily	O
life	O
tasks	O
and	O
increase	O
the	O
risk	O
of	O
traffic	O
,	O
work	O
,	O
and	O
home	O
accidents	O
and	O
the	O
number	O
of	O
falls	O
and	O
hospitalizations	O
.	O

MHE	B-DS
predisposes	O
to	O
overt	O
HE	B-DS
with	O
more	O
severe	O
symptoms	O
and	O
reduces	O
life	O
span	O
.	O

Early	O
treatment	O
of	O
patients	O
with	O
HE	B-DS
would	O
improve	O
their	O
quality	O
of	O
life	O
and	O
life	O
span	O
and	O
reduce	O
accidents	O
,	O
hospitalizations	O
,	O
and	O
associated	O
costs	O
.	O

Current	O
treatments	O
for	O
HE	B-DS
are	O
mainly	O
directed	O
to	O
reduction	O
of	O
ammonia	O
levels	O
with	O
the	O
use	O
of	O
nonabsorbable	O
disaccharides	O
or	O
antibiotics	O
such	O
as	O
neomycin	O
or	O
rifaximin	O
.	O

Probiotics	O
are	O
also	O
beginning	O
to	O
be	O
tested	O
.	O

However	O
,	O
these	O
treatments	O
are	O
not	O
completely	O
effective	O
in	O
reducing	O
the	O
neurological	O
alterations	O
,	O
as	O
they	O
cannot	O
eliminate	O
hyperammonemia	B-DS
or	O
inflammation	O
continuously	O
generated	O
by	O
the	O
liver	B-DS
disease	I-DS
(	O
14	O
,	O
30	O
,	O
35	O
).	O

Studies	O
in	O
animal	B-OG
HE	B-DS
models	O
have	O
identified	O
cerebral	O
mechanisms	O
responsible	O
for	O
cognitive	O
and	O
motor	O
alterations	O
and	O
brain	O
targets	O
modulation	O
of	O
which	O
reverses	O
cognitive	O
and	O
motor	O
alterations	O
in	O
rats	B-OG
with	O
HE	B-DS
,	O
while	O
hyperammonemia	B-DS
and	O
inflammation	O
remain	O
present	O
(	O
15	O
).	O

A	O
main	O
contributor	O
to	O
cognitive	O
and	O
motor	O
deficits	O
in	O
HE	B-DS
is	O
increased	O
GABAergic	O
tone	O
(	O
increased	O
activation	O
of	O
GABAA	B-GP
receptors	I-GP
).	O

Increased	O
GABAergic	O
tone	O
induces	O
motor	O
incoordination	O
,	O
and	O
extracellular	O
GABA	O
in	O
cerebellum	O
correlates	O
with	O
motor	O
incoordination	O
in	O
rats	B-OG
(	O
9	O
).	O
α1	O
-	O
Containing	O
GABAA	B-GP
receptors	I-GP
are	O
likely	O
involved	O
in	O
the	O
motor	O
incoordination	O
since	O
benzodiazepines	O
induce	O
ataxia	B-DS
by	O
enhancing	O
activation	O
of	O
α1	O
-	O
containing	O
GABAA	B-GP
receptors	I-GP
(	O
27	O
).	O

Furthermore	O
,	O
overactivation	O
of	O
GABAA	B-GP
receptors	I-GP
by	O
the	O
agonists	O
diazepam	O
and	O
muscimol	O
or	O
the	O
neurosteroids	O
allopregnanolone	O
and	O
3α	O
,	O
21	O
-	O
dihydroxy	O
-	O
5α	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
(	O
THDOC	O
)	O
impairs	O
spatial	O
learning	O
and	O
memory	O
in	O
the	O
Morris	O
water	O
maze	O
(	O
19	O
,	O
33	O
,	O
34	O
).	O

GABAergic	O
tone	O
is	O
increased	O
in	O
the	O
cerebellum	O
of	O
rats	B-OG
with	O
chronic	O
hyperammonemia	B-DS
and	O
HE	B-DS
because	O
of	O
increased	O
extracellular	O
GABA	O
and	O
increased	O
levels	O
of	O
neurosteroids	O
acting	O
as	O
positive	O
modulators	O
of	O
GABAA	B-GP
receptors	I-GP
(	O
allopregnanolone	O
,	O
THDOC	O
)	O
(	O
12	O
).	O

Allopregnanolone	O
is	O
increased	O
in	O
the	O
brain	O
of	O
cirrhotic	O
patients	O
who	O
die	O
in	O
HE	B-DS
(	O
3	O
),	O
and	O
allopregnanolone	O
and	O
THDOC	O
are	O
increased	O
in	O
rats	B-OG
with	O
hyperammonemia	B-DS
(	O
12	O
)	O
or	O
portacaval	O
anastomosis	O
(	O
4	O
,	O
5	O
).	O

Hence	O
,	O
the	O
neurosteroid	O
system	O
seems	O
to	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
HE	B-DS
and	O
is	O
an	O
attractive	O
therapeutic	O
target	O
for	O
treatment	O
of	O
HE	B-DS
(	O
4	O
,	O
6	O
).	O

Reducing	O
GABAergic	O
tone	O
with	O
the	O
GABAA	B-GP
receptor	I-GP
antagonist	O
bicuculline	O
or	O
the	O
GABAA	B-GP
receptor	I-GP
negative	O
allosteric	O
modulator	O
pregnenolone	O
sulfate	O
improves	O
cognitive	O
function	O
in	O
hyperammonemic	O
rats	B-OG
(	O
12	O
,	O
17	O
).	O

However	O
,	O
these	O
compounds	O
would	O
not	O
be	O
good	O
therapeutic	O
agents	O
,	O
pregnenolone	O
sulfate	O
because	O
it	O
does	O
not	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
bicuculline	O
and	O
finasteride	O
because	O
they	O
may	O
have	O
serious	O
side	O
effects	O
.	O

Bicuculline	O
has	O
been	O
shown	O
to	O
induce	O
seizures	O
,	O
epilepsy	B-DS
,	O
and	O
convulsions	O
(	O
8	O
,	O
37	O
,	O
40	O
)	O
and	O
may	O
also	O
induce	O
cardiovascular	O
alterations	O
and	O
increase	O
blood	O
pressure	O
and	O
heart	O
rate	O
(	O
24	O
).	O

Finasteride	O
may	O
have	O
adverse	O
effects	O
on	O
sexual	O
function	O
,	O
high	O
-	O
grade	O
prostate	B-DS
cancer	I-DS
incidence	O
,	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
function	O
,	O
and	O
depression	B-DS
(	O
38	O
).	O

Modulation	O
of	O
GABAergic	O
tone	O
by	O
acting	O
on	O
the	O
neurosteroid	O
system	O
could	O
thus	O
have	O
more	O
therapeutic	O
benefits	O
.	O

In	O
this	O
line	O
,	O
inhibition	O
of	O
neurosteroid	O
synthesis	O
with	O
finasteride	O
improves	O
symptoms	O
and	O
prevents	O
hepatic	B-DS
coma	I-DS
in	O
thioacetamide	O
(	O
TAA	O
)-	O
induced	O
HE	B-DS
(	O
28	O
).	O

However	O
,	O
the	O
use	O
of	O
finasteride	O
in	O
patients	O
is	O
limited	O
by	O
its	O
side	O
effects	O
.	O

We	O
have	O
developed	O
a	O
new	O
compound	O
,	O
GR3027	O
,	O
that	O
selectively	O
antagonizes	O
the	O
enhanced	O
activation	O
of	O
GABAA	B-GP
receptors	I-GP
by	O
neurosteroids	O
such	O
as	O
allopregnanolone	O
and	O
THDOC	O
.	O

The	O
aims	O
were	O
to	O
assess	O
whether	O
GR3027	O
improves	O
motor	O
incoordination	O
and	O
spatial	O
learning	O
in	O
rats	B-OG
with	O
chronic	O
hyperammonemia	B-DS
or	O
with	O
portacaval	O
anastomosis	O
,	O
two	O
main	O
models	O
of	O
HE	B-DS
recommended	O
by	O
the	O
International	O
Society	O
for	O
Hepatic	B-DS
Encephalopathy	I-DS
(	O
10	O
).	O

MATERIALS	O
AND	O
METHODS	O

GR3027	O
is	O
a	O
3β	O
-	O
hydroxysteroid	O
within	O
a	O
series	O
of	O
molecules	O
developed	O
and	O
patented	O
by	O
some	O
of	O
the	O
authors	O
(	O
T	O
.	O

Bäckström	O
and	O
G	O
.	O

Ragagnin	O
)	O
for	O
the	O
treatment	O
of	O
CNS	B-DS
disorders	I-DS
(	O
patent	O
WO	O
2008	O
/	O
063128	O
).	O

3β	O
-	O
Hydroxysteroids	O
are	O
functional	O
antagonists	O
against	O
3α	O
-	O
hydroxysteroids	O
that	O
positively	O
modulate	O
GABAA	B-GP
receptors	I-GP
(	O
36	O
,	O
42	O
,	O
43	O
).	O

GABAA	B-GP
Receptor	I-GP
Pharmacology	O

HEK293	O
cells	O
were	O
permanently	O
transfected	O
to	O
constitutively	O
express	O
the	O
human	B-OG
α5	O
,	O
β3	O
,	O
and	O
γ2L	O
or	O
α1	O
,	O
β2	O
,	O
and	O
γ2L	B-GP
GABAA	I-GP
receptor	I-GP
subunits	O
,	O
respectively	O
.	O

Cells	O
were	O
detached	O
by	O
trypsin	B-GP
,	O
incubated	O
for	O
15	O
min	O
at	O
37	O
°	O
C	O
in	O
extracellular	O
(	O
EC	O
)	O
solution	O
(	O
in	O
mM	O
:	O
137	O
NaCl	O
,	O
5	O
.	O
0	O
KCl	O
,	O
1	O
.	O
0	O
CaCl2	O
,	O
1	O
.	O
2	O
MgCl2	O
,	O
10	O
HEPES	O
,	O
and	O
10	O
glucose	O
,	O
pH	O
7	O
.	O
4	O
),	O
and	O
added	O
to	O
the	O
EC	O
solution	O
in	O
the	O
chip	O
bath	O
(	O
Dynaflow	O
Resolve	O
,	O
Cellectricon	O
).	O

Whole	O
cell	O
recordings	O
were	O
performed	O
under	O
voltage	O
-	O
clamp	O
conditions	O
.	O

Recordings	O
were	O
performed	O
at	O
room	O
temperature	O
and	O
−	O
17	O
mV	O
(	O
corrected	O
for	O
liquid	O
junction	O
potential	O
)	O
with	O
an	O
AxonPatch	O
200B	O
amplifier	O
and	O
a	O
DigiData	O
1322A	O
converter	O
.	O

Data	O
were	O
acquired	O
with	O
pCLAMP	O
9	O
.	O
0	O
and	O
analyzed	O
with	O
Clampfit	O
9	O
.	O
0	O
(	O
Axon	O
Instruments	O
,	O
Foster	O
City	O
,	O
CA	O
).	O

Patch	O
electrodes	O
(	O
1	O
.	O
5	O
–	O
4	O
MΩ	O
)	O
were	O
filled	O
with	O
intracellular	O
solution	O
(	O
in	O
mM	O
:	O
140	O
Cs	O
-	O
gluconate	O
,	O
3	O
.	O
0	O
NaCl	O
,	O
1	O
.	O
2	O
MgCl2	O
,	O
10	O
HEPES	O
,	O
1	O
.	O
0	O
EGTA	O
,	O
2	O
MgATP	O
,	O
pH	O
7	O
.	O
2	O
).	O

THDOC	O
and	O
GR3027	O
were	O
dissolved	O
in	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
and	O
diluted	O
in	O
EC	O
solution	O
;	O
at	O
measurements	O
all	O
solutions	O
contained	O
0	O
.	O
1	O
%	O
DMSO	O
.	O

Different	O
protocols	O
were	O
used	O
for	O
different	O
electrophysiology	O
measurements	O
,	O
as	O
the	O
GABAA	B-GP
receptor	I-GP
subunit	O
combinations	O
studied	O
are	O
present	O
in	O
different	O
parts	O
of	O
neurons	O
[	O
recently	O
reviewed	O
by	O
Carver	O
and	O
Reddy	O
(	O
11	O
)].	O

As	O
α1β2γ2L	B-GP
-	O
GABAA	B-GP
receptors	I-GP
are	O
present	O
within	O
the	O
synapse	O
in	O
vivo	O
,	O
experimental	O
conditions	O
resembling	O
that	O
situation	O
,	O
a	O
short	O
application	O
(	O
40	O
ms	O
)	O
of	O
a	O
high	O
GABA	O
concentration	O
(	O
30	O
μM	O
),	O
were	O
used	O
.	O

In	O
contrast	O
,	O
α5β3γ2L	B-GP
-	O
GABAA	B-GP
receptors	I-GP
are	O
present	O
extrasynaptically	O
in	O
vivo	O
,	O
and	O
thus	O
the	O
experimental	O
conditions	O
used	O
were	O
long	O
exposures	O
(	O
6	O
s	O
)	O
to	O
a	O
low	O
GABA	O
concentration	O
(	O
0	O
.	O
3	O
μM	O
).	O

With	O
both	O
cell	O
types	O
the	O
EC75s	O
of	O
THDOC	O
were	O
used	O
,	O
i	O
.	O
e	O
.,	O
100	O
nM	O
for	O
studies	O
of	O
α1β2γ2L	B-GP
and	O
200	O
nM	O
when	O
α5β3γ2L	B-GP
-	O
expressing	O
cells	O
were	O
evaluated	O
.	O

Cells	O
were	O
preexposed	O
to	O
THDOC	O
alone	O
or	O
to	O
THDOC	O
in	O
the	O
presence	O
of	O
GR3027	O
before	O
the	O
GABA	O
application	O
.	O

In	O
each	O
cell	O
effects	O
were	O
normalized	O
to	O
the	O
control	O
response	O
and	O
the	O
area	O
under	O
the	O
curve	O
was	O
analyzed	O
.	O

Off	O
-	O
Target	O
Profiling	O

The	O
binding	O
of	O
GR3027	O
was	O
determined	O
for	O
receptors	O
,	O
ion	B-GP
channels	I-GP
,	O
and	O
enzymes	O
,	O
including	O
all	O
major	O
classes	O
of	O
neurotransmitter	B-GP
receptors	I-GP
.	O

A	O
total	O
of	O
114	O
targets	O
(	O
Table	O
1	O
)	O
were	O
tested	O
in	O
duplicate	O
with	O
GR3027	O
at	O
10	O
μM	O
(	O
PerkinElmer	O
,	O
customized	O
screen	O
).	O

Binding	O
activity	O
was	O
defined	O
as	O
≥	O
50	O
%	O
inhibition	O
of	O
ligand	O
binding	O
.	O

Targets	O
in	O
binding	O
studies	O
with	O
GR3027	O

Adenosine	B-GP
A1	I-GP
receptor	I-GP

Angiotensin	B-GP
II	I-GP
,	I-GP
AT1	I-GP
receptor	I-GP

Adenosine	B-GP
A2A	I-GP
receptor	I-GP

Angiotensin	B-GP
II	I-GP
,	I-GP
AT2	I-GP
receptor	I-GP

Adenosine	B-GP
A3	I-GP
receptor	I-GP

Bradykinin	B-GP
receptor	I-GP

Adrenergic	B-GP
alpha	I-GP
1A	I-GP
receptor	I-GP

Cholecystokinin	B-GP
CCK1	I-GP
receptor	I-GP

Adrenergic	B-GP
alpha	I-GP
1B	I-GP
receptor	I-GP

Cholecystokinin	B-GP
CCK2	I-GP
receptor	I-GP

Adrenergic	B-GP
alpha	I-GP
2A	I-GP
receptor	I-GP

Endothelin	B-GP
receptor	I-GP
A	I-GP

Adrenergic	B-GP
alpha	I-GP
2B	I-GP
receptor	I-GP

Endothelin	B-GP
receptor	I-GP
B	I-GP

Adrenergic	B-GP
Alpha	I-GP
2C	I-GP
receptor	I-GP

Galanin	B-GP
receptor	I-GP

Adrenergic	B-GP
beta	I-GP
1	I-GP
receptor	I-GP

Neurokinin	B-GP
1	I-GP
receptor	I-GP

Adrenergic	B-GP
beta	I-GP
2	I-GP
receptor	I-GP

Neurokinin	B-GP
2	I-GP
receptor	I-GP

Adrenergic	B-GP
beta	I-GP
3	I-GP
receptor	I-GP

Neurokinin	B-GP
3	I-GP
receptor	I-GP

Cannabinoid	B-GP
CB1	I-GP
receptor	I-GP

Neuropeptide	B-GP
Y	I-GP
receptor	I-GP
Y1	I-GP

Cannabinoid	B-GP
CB2	I-GP
receptor	I-GP

Neuropeptide	B-GP
Y	I-GP
receptor	I-GP
Y2	I-GP

Dopamine	B-GP
transporter	I-GP

Vasoactive	B-GP
intestinal	I-GP
peptide	I-GP
receptor	I-GP

Dopamine	B-GP
D1	I-GP
receptor	I-GP

Vasopressin	B-GP
receptor	I-GP
1	I-GP

Dopamine	B-GP
D2	I-GP
s	I-GP
receptor	I-GP

Calcium	B-GP
channel	I-GP
type	I-GP
L	I-GP
,	O
BDZ	O
site	O

Dopamine	B-GP
D3	I-GP
receptor	I-GP

Calcium	B-GP
channel	I-GP
type	I-GP
L	I-GP
,	O
dihydropyridine	O
site	O

Dopamine	B-GP
D4	I-GP
.	I-GP
4	I-GP
receptor	I-GP

Calcium	B-GP
channel	I-GP
type	I-GP
N	I-GP

GABA	B-GP
transporter	I-GP

Potassium	B-GP
channel	I-GP
,	I-GP
ATP	I-GP
-	I-GP
sensitive	I-GP

GABA	B-GP
-	I-GP
A	I-GP
receptor	I-GP
,	O
agonist	O
site	O

Potassium	B-GP
channel	I-GP
,	I-GP
Ca2	I-GP
+-	I-GP
activated	I-GP

GABA	B-GP
-	I-GP
A	I-GP
receptor	I-GP
,	I-GP
α1	I-GP
,	O
benzodiazepine	O
site	O

Potassium	B-GP
channel	I-GP
,	I-GP
hERG	I-GP

GABA	B-GP
-	I-GP
A	I-GP
receptor	I-GP
,	I-GP
α6	I-GP
,	O
benzodiazepine	O
site	O

Sodium	B-GP
channel	I-GP
,	O
site	O
2	O

GABA	B-GP
-	I-GP
A	I-GP
receptor	I-GP
,	O
chloride	B-GP
channel	I-GP

Adenylate	B-GP
cyclase	I-GP
,	O
forskolin	O

GABA	B-GP
-	I-GP
B	I-GP
receptor	I-GP

Nitric	B-GP
oxide	I-GP
synthase	I-GP

Glutamate	B-GP
receptor	I-GP
,	O
AMPA	O
site	O

Protein	B-GP
kinase	I-GP
C	I-GP

Glutamate	B-GP
receptor	I-GP
,	O
kainate	O
site	O

Carbonic	B-GP
anhydrase	I-GP
1	I-GP

Glutamate	B-GP
receptor	I-GP
,	O
MK	O
-	O
801	O
site	O

Carbonic	B-GP
anhydrase	I-GP
2	I-GP

Glutamate	B-GP
receptor	I-GP
,	O
NMDA	O
agonist	O
site	O

Histone	B-GP
deacetylase	I-GP
3	I-GP

Glutamate	B-GP
receptor	I-GP
,	O
NMDA	O
,	O
glycine	O
site	O

Histone	B-GP
deacetylase	I-GP
6	I-GP

Glycine	B-GP
receptor	I-GP
,	O
strychnine	O
-	O
sensitive	O
site	O

Histone	B-GP
deacetylase	I-GP
8	I-GP

Histamine	B-GP
H1	I-GP
receptor	I-GP

Histone	B-GP
deacetylase	I-GP
sirtuin	I-GP
1	I-GP

Histamine	B-GP
H2	I-GP
receptor	I-GP

Histone	B-GP
deacetylase	I-GP
sirtuin	I-GP
2	I-GP

Histamine	B-GP
H3	I-GP
receptor	I-GP

Histone	B-GP
deacetylase	I-GP
sirtuin	I-GP
3	I-GP

Imidazoline	B-GP
I2	I-GP
receptor	I-GP

Plasma	O
esterase	B-GP

Melatonin	B-GP
receptor	I-GP

Monoamine	B-GP
oxidase	I-GP
A	I-GP
,	I-GP
peripheral	I-GP

Translocator	B-GP
protein	I-GP
(	O
TSPO	B-GP
)	O

Monoamine	B-GP
oxidase	I-GP
B	I-GP
,	I-GP
peripheral	I-GP

Muscarinic	B-GP
M1	I-GP
receptor	I-GP

Cyclooxygenase	B-GP
1	I-GP

Muscarinic	O
M2	O
receptor	O

Cyclooxygenase	B-GP
2	I-GP

Muscarinic	B-GP
M3	I-GP
receptor	I-GP

Serine	B-GP
/	I-GP
threonine	I-GP
phosphatase	I-GP
,	I-GP
PP1a	I-GP

Muscarinic	B-GP
M4	I-GP
receptor	I-GP

Serine	B-GP
/	I-GP
threonine	I-GP
phosphatase	I-GP
,	I-GP
PP2a	I-GP

Muscarinic	B-GP
M5	I-GP
receptor	I-GP

Phosphodiesterase	B-GP
4A1A	I-GP

Nicotinic	B-GP
receptor	I-GP
,	I-GP
neuronal	I-GP

Phosphodiesterase	B-GP
5A1	I-GP

Norepinephrine	B-GP
transporter	I-GP

Protease	B-GP
ACE1	I-GP

Opioid	O
receptor	O
,	O
delta	O
2	O

Protease	B-GP
elastase	I-GP

Opioid	B-GP
receptor	I-GP
,	I-GP
kappa	I-GP
1	I-GP

Matrix	B-GP
metalloprotease	I-GP
2	I-GP

Opioid	B-GP
receptor	I-GP
,	I-GP
mu	I-GP

Matrix	B-GP
metalloprotease	I-GP
3	I-GP

Opioid	B-GP
receptor	I-GP
,	I-GP
Orphanin	I-GP
,	I-GP
ORL1	I-GP

Cyclin	B-GP
-	I-GP
dependent	I-GP
kinase	I-GP
2	I-GP

Purinergic	B-GP
P2Y	I-GP
receptor	I-GP

Calcium	B-GP
/	I-GP
calmodulin	I-GP
-	I-GP
dependent	I-GP
kinase	I-GP
2A	I-GP

Serotonin	B-GP
receptor	I-GP
,	I-GP
nonselective	I-GP

Epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP

Sigma	B-GP
receptor	I-GP
,	I-GP
nonselective	I-GP

Ephrin	B-GP
type	I-GP
-	I-GP
A	I-GP
receptor	I-GP

Estrogen	B-GP
receptor	I-GP
alpha	I-GP

Inhibitor	B-GP
of	I-GP
nuclear	I-GP
factor	I-GP
kappa	I-GP
-	I-GP
B	I-GP
kinase	I-GP
,	I-GP
b	I-GP

Glucocorticoid	B-GP
receptor	I-GP
,	O
ligand	O
domain	O

Insulin	B-GP
receptor	I-GP

Progesterone	B-GP
receptor	I-GP

Mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
C	I-GP

Testosterone	B-GP
receptor	I-GP
,	I-GP
cytosolic	I-GP

Protein	B-GP
kinase	I-GP
C	I-GP
-	I-GP
alpha	I-GP

Corticotropin	B-GP
-	I-GP
releasing	I-GP
factor	I-GP
receptor	I-GP

Protein	B-GP
kinase	I-GP
C	I-GP
-	I-GP
eta	I-GP

Platelet	B-GP
-	I-GP
activating	I-GP
factor	I-GP
receptor	I-GP

Proto	B-GP
-	I-GP
oncogene	I-GP
tyrosine	I-GP
-	I-GP
protein	I-GP
kinase	I-GP
Src	I-GP

Thyrotropin	B-GP
-	I-GP
releasing	I-GP
hormone	I-GP
receptor	I-GP

Zeta	B-GP
-	I-GP
chain	I-GP
-	I-GP
associated	I-GP
protein	I-GP
kinase	I-GP
70	I-GP

Binding	O
targets	O
for	O
studies	O
with	O
10	O
μM	O
GR3027	O
are	O
shown	O
.	O

Chronic	O
Hyperammonemia	B-DS
in	O
Rats	B-OG

Male	O
Wistar	B-OG
rats	I-OG
(	O
140	O
–	O
160	O
g	O
)	O
were	O
made	O
hyperammonemic	O
by	O
feeding	O
with	O
a	O
diet	O
containing	O
25	O
%	O
ammonium	O
acetate	O
(	O
16	O
).	O

These	O
rats	B-OG
become	O
hyperammonemic	O
,	O
with	O
two	O
-	O
to	O
threefold	O
increase	O
in	O
blood	O
ammonia	O
and	O
∼	O
40	O
%	O
increase	O
in	O
the	O
brain	O
(	O
7	O
).	O

Control	O
rats	B-OG
were	O
fed	O
normal	O
chow	O
.	O

Portacaval	O
Anastomosis	O

Male	O
Wistar	B-OG
rats	I-OG
(	O
220	O
–	O
240	O
g	O
)	O
were	O
subjected	O
to	O
portacaval	O
anastomosis	O
.	O

Rats	B-OG
were	O
anesthetized	O
,	O
and	O
an	O
end	O
-	O
to	O
-	O
side	O
portacaval	O
anastomosis	O
was	O
constructed	O
under	O
aseptic	O
conditions	O
with	O
a	O
continuous	O
suture	O
technique	O
according	O
to	O
the	O
technique	O
of	O
Lee	O
and	O
Fisher	O
(	O
21	O
).	O

The	O
inferior	O
vena	O
cava	O
and	O
portal	O
vein	O
were	O
clamped	O
for	O
not	O
more	O
than	O
15	O
min	O
;	O
after	O
unclamping	O
,	O
the	O
bowel	O
was	O
evaluated	O
for	O
cyanosis	O
.	O

If	O
cyanosis	O
persisted	O
,	O
the	O
animal	B-OG
was	O
killed	O
.	O

Control	O
rats	B-OG
were	O
sham	O
operated	O
.	O

Sham	O
-	O
operated	O
rats	B-OG
had	O
their	O
portal	O
vein	O
and	O
inferior	O
vena	O
cava	O
clamped	O
for	O
10	O
min	O
.	O

After	O
satisfactory	O
surgery	O
,	O
the	O
abdomen	O
was	O
sutured	O
in	O
two	O
layers	O
and	O
rats	B-OG
were	O
returned	O
to	O
their	O
individual	O
cages	O
.	O

Adequate	O
measures	O
were	O
taken	O
to	O
minimize	O
pain	O
and	O
discomfort	O
to	O
the	O
animals	B-OG
.	O

The	O
experiments	O
were	O
approved	O
by	O
the	O
Comite	O
de	O
Experimentación	O
y	O
Bienestar	O
Animal	B-OG
of	O
our	O
Center	O
and	O
performed	O
in	O
accordance	O
with	O
guidelines	O
of	O
the	O
Directive	O
of	O
the	O
European	O
Commission	O
(	O
2010	O
/	O
63	O
/	O
EU	O
)	O
for	O
care	O
and	O
management	O
of	O
experimental	O
animals	B-OG
.	O

Treatment	O
with	O
GR3027	O

GR3027	O
in	O
sesame	B-OG
oil	O
was	O
administered	O
by	O
daily	O
subcutaneous	O
injections	O
in	O
the	O
back	O
.	O

Two	O
different	O
sets	O
of	O
experiments	O
were	O
performed	O
in	O
hyperammonemic	O
rats	B-OG
.	O

In	O
the	O
first	O
set	O
four	O
groups	O
of	O
rats	B-OG
were	O
used	O
:	O
1	O
)	O
control	O
rats	B-OG
injected	O
with	O
vehicle	O
,	O
2	O
)	O
hyperammonemic	O
rats	B-OG
injected	O
with	O
vehicle	O
,	O
3	O
)	O
control	O
rats	B-OG
injected	O
with	O
20	O
mg	O
/	O
kg	O
GR3027	O
,	O
and	O
4	O
)	O
hyperammonemic	O
rats	B-OG
injected	O
with	O
20	O
mg	O
/	O
kg	O
GR3027	O
.	O

Control	O
rats	B-OG
injected	O
with	O
GR3027	O
were	O
not	O
included	O
subsequently	O
because	O
no	O
relevant	O
effect	O
was	O
found	O
in	O
these	O
rats	B-OG
.	O

In	O
the	O
second	O
set	O
of	O
experiments	O
five	O
groups	O
of	O
rats	B-OG
were	O
used	O
:	O
1	O
)	O
control	O
rats	B-OG
injected	O
with	O
vehicle	O
,	O
2	O
)	O
hyperammonemic	O
rats	B-OG
injected	O
with	O
vehicle	O
,	O
and	O
hyperammonemic	O
rats	B-OG
injected	O
with	O
3	O
)	O
3	O
,	O
4	O
)	O
10	O
,	O
or	O
5	O
)	O
20	O
mg	O
/	O
kg	O
GR3027	O
.	O

Numbers	O
of	O
rats	B-OG
are	O
indicated	O
in	O
figures	O
.	O

In	O
rats	B-OG
GR3027	O
is	O
metabolized	O
in	O
the	O
liver	O
,	O
and	O
GR3027	O
dosage	O
adjustments	O
were	O
made	O
in	O
the	O
portacaval	O
shunt	O
(	O
PCS	O
)	O
rats	B-OG
to	O
compensate	O
for	O
the	O
metabolic	O
dysfunction	O
caused	O
by	O
the	O
portacaval	O
shunting	O
.	O

For	O
this	O
a	O
prestudy	O
with	O
different	O
doses	O
was	O
performed	O
,	O
and	O
thereafter	O
the	O
following	O
groups	O
were	O
used	O
:	O
1	O
)	O
sham	O
-	O
operated	O
rats	B-OG
injected	O
with	O
vehicle	O
,	O
2	O
)	O
PCS	O
rats	B-OG
injected	O
with	O
vehicle	O
,	O
and	O
PCS	O
rats	B-OG
injected	O
with	O
3	O
)	O
0	O
.	O
7	O
or	O
4	O
)	O
2	O
.	O
5	O
mg	O
/	O
kg	O
GR3027	O
.	O

Numbers	O
of	O
rats	B-OG
are	O
indicated	O
in	O
figures	O
.	O

The	O
reason	O
that	O
the	O
doses	O
used	O
in	O
the	O
studies	O
with	O
hyperammonemic	O
and	O
PCS	O
rats	B-OG
are	O
different	O
is	O
that	O
GR3027	O
is	O
metabolized	O
by	O
the	O
liver	O
in	O
rats	B-OG
and	O
we	O
expected	O
a	O
reduced	O
metabolism	O
of	O
GR3027	O
in	O
PCS	O
compared	O
with	O
control	O
or	O
hyperammonemic	O
rats	B-OG
.	O

For	O
this	O
reason	O
we	O
performed	O
prestudies	O
with	O
different	O
doses	O
of	O
GR3027	O
in	O
PCS	O
rats	B-OG
to	O
find	O
the	O
doses	O
giving	O
equal	O
exposures	O
in	O
the	O
two	O
rat	B-OG
models	O
.	O

The	O
doses	O
were	O
then	O
reduced	O
in	O
the	O
experiments	O
with	O
PCS	O
rats	B-OG
compared	O
with	O
those	O
with	O
hyperammonemic	O
rats	B-OG
.	O

As	O
shown	O
in	O
Fig	O
.	O
7	O
,	O
the	O
levels	O
of	O
GR3027	O
reached	O
in	O
plasma	O
and	O
brain	O
were	O
similar	O
in	O
hyperammonemic	O
and	O
PCS	O
rats	B-OG
.	O

Experimental	O
Design	O

The	O
experimental	O
design	O
,	O
including	O
the	O
treatment	O
period	O
and	O
the	O
time	O
at	O
which	O
the	O
behavioral	O
tests	O
were	O
conducted	O
in	O
the	O
two	O
experimental	O
models	O
,	O
is	O
shown	O
in	O
Fig	O
.	O
1	O
.	O

Scheme	O
showing	O
the	O
experimental	O
design	O
for	O
hyperammonemic	O
(	O
HA	O
;	O
A	O
)	O
rats	B-OG
and	O
portacaval	O
shunt	O
(	O
PCS	O
;	O
B	O
)	O
rats	B-OG
.	O

Motor	O
coordination	O
:	O
beam	O
walking	O
test	O
.	O

Motor	O
coordination	O
was	O
tested	O
as	O
described	O
in	O
Gonzalez	O
-	O
Usano	O
et	O
al	O
.	O
(	O
17	O
)	O
with	O
a	O
wood	O
strip	O
(	O
20	O
-	O
mm	O
diameter	O
).	O

The	O
number	O
of	O
foot	O
faults	O
(	O
slips	O
)	O
was	O
manually	O
recorded	O
as	O
a	O
measure	O
of	O
incoordination	O
.	O

Spatial	O
learning	O
in	O
Morris	O
water	O
maze	O
.	O

The	O
test	O
was	O
performed	O
as	O
in	O
Monfort	O
et	O
al	O
.	O
(	O
29	O
)	O
with	O
a	O
circular	O
pool	O
(	O
160	O
×	O
40	O
cm	O
).	O

After	O
pretraining	O
,	O
the	O
rats	B-OG
were	O
trained	O
to	O
learn	O
the	O
fixed	O
location	O
of	O
the	O
invisible	O
platform	O
over	O
3	O
days	O
.	O

Training	O
consisted	O
of	O
three	O
swims	O
per	O
day	O
.	O

The	O
time	O
needed	O
to	O
find	O
the	O
hidden	O
platform	O
was	O
recorded	O
as	O
a	O
measure	O
of	O
learning	O
.	O

Spatial	O
memory	O
was	O
assessed	O
24	O
h	O
later	O
by	O
removing	O
the	O
platform	O
and	O
measuring	O
the	O
time	O
spent	O
in	O
the	O
quadrant	O
where	O
it	O
was	O
previously	O
positioned	O
.	O

Spatial	O
learning	O
in	O
eight	O
-	O
arm	O
radial	O
maze	O
.	O

Training	O
was	O
composed	O
of	O
three	O
trials	O
per	O
day	O
over	O
6	O
days	O
.	O

The	O
task	O
involved	O
locating	O
four	O
pellets	O
placed	O
at	O
the	O
end	O
of	O
different	O
arms	O
according	O
to	O
a	O
random	O
configuration	O
as	O
in	O
Hernandez	O
-	O
Rabaza	O
et	O
al	O
.	O
(	O
18	O
).	O

The	O
number	O
of	O
working	O
memory	O
errors	O
(	O
visits	O
to	O
arms	O
already	O
visited	O
in	O
the	O
same	O
trial	O
)	O
were	O
recorded	O
.	O

Circadian	O
rhythms	O
of	O
locomotor	O
activity	O
.	O

Motor	O
activity	O
was	O
recorded	O
continuously	O
at	O
intervals	O
of	O
5	O
min	O
for	O
14	O
days	O
in	O
a	O
12	O
:	O
12	O
-	O
h	O
light	O
-	O
dark	O
cycle	O
with	O
an	O
actimeter	O
of	O
infrared	O
motion	O
detection	O
as	O
in	O
Ahabrach	O
et	O
al	O
.	O
(	O
1	O
).	O

Ambulatory	O
counts	O
and	O
vertical	O
counts	O
were	O
recorded	O
(	O
1	O
).	O

Activity	O
was	O
detected	O
by	O
arrays	O
of	O
infrared	O
motion	O
detection	O
,	O
with	O
two	O
arrays	O
1	O
cm	O
above	O
the	O
floor	O
of	O
the	O
chamber	O
and	O
another	O
array	O
6	O
cm	O
above	O
the	O
floor	O
.	O

One	O
ambulatory	O
count	O
is	O
recorded	O
when	O
the	O
rats	B-OG
interrupted	O
three	O
consecutive	O
infrared	O
detectors	O
.	O

One	O
vertical	O
count	O
is	O
recorded	O
when	O
the	O
rats	B-OG
interrupted	O
the	O
above	O
detectors	O
.	O

Determination	O
of	O
ammonia	O
.	O

Blood	O
ammonia	O
was	O
measured	O
with	O
the	O
II	O
Ammonia	O
Arkray	O
test	O
kit	O
(	O
PocketChem	O
BA	O
,	O
Arkray	O
)	O
using	O
20	O
μl	O
of	O
blood	O
.	O

GR3027	O
exposure	O
.	O

At	O
the	O
end	O
of	O
treatment	O
plasma	O
was	O
collected	O
from	O
the	O
tail	O
vein	O
.	O

After	O
death	O
by	O
decapitation	O
brains	O
were	O
collected	O
and	O
frozen	O
on	O
dry	O
ice	O
.	O

For	O
analysis	O
of	O
GR3027	O
,	O
brain	O
tissue	O
was	O
homogenized	O
with	O
a	O
1	O
-	O
to	O
-	O
4	O
ratio	O
of	O
tissue	O
to	O
PBS	O
(	O
pH	O
7	O
.	O
4	O
)	O
and	O
extracted	O
with	O
2	O
volumes	O
of	O
methanol	O
-	O
acetonitrile	O
(	O
1	O
:	O
1	O
).	O

Plasma	O
protein	O
was	O
precipitated	O
with	O
3	O
volumes	O
of	O
acetonitrile	O
.	O

Analyses	O
were	O
performed	O
with	O
a	O
Waters	O
ACQUITY	O
UPLC	O
+	O
Waters	O
XEVO	O
-	O
TQS	O
triple	O
quadrupole	O
mass	O
spectrometer	O
(	O
Admescope	O
,	O
Oulu	O
,	O
Finland	O
).	O

For	O
calculations	O
of	O
the	O
amount	O
of	O
free	O
GR3027	O
in	O
the	O
brain	O
the	O
fraction	O
unbound	O
(	O
Fub	O
)	O
in	O
brain	O
homogenates	O
was	O
determined	O
by	O
dialysis	O
:	O
Fub	O
in	O
hyperammonemia	B-DS
=	O
0	O
.	O
70	O
%	O
and	O
Fub	O
in	O
PCS	O
=	O
1	O
.	O
43	O
%	O
(	O
Admescope	O
).	O

Statistical	O
Analysis	O

All	O
data	O
are	O
shown	O
as	O
means	O
±	O
SE	O
.	O

Electrophysiology	O
.	O

Each	O
data	O
point	O
has	O
its	O
own	O
control	O
;	O
n	O
=	O
number	O
of	O
data	O
points	O
pooled	O
from	O
3	O
–	O
11	O
cells	O
.	O

Kruskal	O
-	O
Wallis	O
test	O
followed	O
by	O
the	O
paired	O
nonparametric	O
Wilcoxon	O
signed	O
-	O
ranks	O
test	O
(	O
2	O
related	O
samples	O
)	O
were	O
used	O
to	O
evaluate	O
effects	O
of	O
GR3027	O
.	O

SPSS	O
statistical	O
package	O
versions	O
PASW	O
19	O
.	O
0	O
and	O
22	O
were	O
used	O
for	O
all	O
statistical	O
tests	O
.	O

Animal	B-OG
data	O
.	O

Statistical	O
significance	O
was	O
estimated	O
with	O
two	O
-	O
way	O
ANOVA	O
and	O
Bonferroni	O
post	O
hoc	O
test	O
and	O
with	O
Student	O
'	O
s	O
t	O
-	O
test	O
when	O
only	O
one	O
parameter	O
was	O
compared	O
with	O
GraphPad	O
Prism	O
(	O
La	O
Jolla	O
,	O
CA	O
).	O

RESULTS	O

GR3027	O
Antagonizes	O
THDOC	O
but	O
not	O
GABA	O
at	O
the	O
GABAA	B-GP
Receptor	I-GP

The	O
effects	O
of	O
GR3027	O
were	O
studied	O
with	O
patch	O
-	O
clamp	O
measurements	O
on	O
recombinant	O
HEK293	O
cells	O
expressing	O
human	B-OG
variants	O
of	O
the	O
GABAA	B-GP
receptor	I-GP
.	O

GR3027	O
(	O
1	O
μM	O
)	O
antagonizes	O
the	O
effect	O
of	O
THDOC	O
at	O
both	O
the	O
α1β2γ2L	B-GP
-	O
and	O
α5β3γ2L	B-GP
-	O
subunit	O
variants	O
of	O
the	O
GABAA	B-GP
receptor	I-GP
(	O
Fig	O
.	O
2	O
,	O
A	O
and	O
C	O
).	O

With	O
the	O
α1β2γ2L	B-GP
receptor	I-GP
1	O
μM	O
GR3027	O
inhibits	O
29	O
±	O
5	O
%	O
of	O
THDOC	O
enhancement	O
of	O
the	O
GABA	O
response	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
with	O
the	O
α5β3γ2L	B-GP
receptor	I-GP
the	O
inhibition	O
is	O
49	O
±	O
5	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
experimental	O
conditions	O
used	O
.	O

Representative	O
patch	O
-	O
clamp	O
current	O
measurements	O
showing	O
GR3027	O
antagonism	O
of	O
the	O
3α	O
,	O
21	O
-	O
dihydroxy	O
-	O
5α	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
(	O
THDOC	O
)-	O
enhanced	O
GABA	O
modulation	O
of	O
α1β2γ2L	B-GP
and	O
α5β3γ2L	B-GP
GABAA	I-GP
receptors	I-GP
and	O
no	O
inhibition	O
of	O
GABA	O
.	O
A	O
:	O
1	O
μM	O
GR3027	O
antagonism	O
of	O
100	O
nM	O
THDOC	O
enhanced	O
30	O
μM	O
GABA	O
-	O
mediated	O
current	O
response	O
with	O
the	O
α1β2γ2L	B-GP
GABAA	I-GP
receptor	I-GP
.	O
B	O
:	O
1	O
μM	O
GR3027	O
did	O
not	O
antagonize	O
the	O
30	O
μM	O
GABA	O
response	O
of	O
the	O
α1β2γ2L	B-GP
GABAA	I-GP
receptor	I-GP
.	O
C	O
:	O
concentration	O
response	O
of	O
the	O
GR3027	O
antagonism	O
of	O
100	O
nM	O
THDOC	O
enhanced	O
30	O
μM	O
GABA	O
-	O
mediated	O
current	O
response	O
with	O
the	O
α1β2γ2L	B-GP
GABAA	I-GP
receptor	I-GP
.	O
D	O
:	O
1	O
μM	O
GR3027	O
antagonism	O
of	O
200	O
nM	O
THDOC	O
enhanced	O
0	O
.	O
3	O
μM	O
GABA	O
-	O
mediated	O
current	O
response	O
with	O
the	O
α5β3γ2L	B-GP
GABAA	I-GP
receptor	I-GP
.	O
E	O
:	O
1	O
μM	O
GR3027	O
did	O
not	O
antagonize	O
the	O
0	O
.	O
3	O
μM	O
GABA	O
response	O
of	O
the	O
α5β3γ2L	B-GP
GABAA	I-GP
receptor	I-GP
.	O
F	O
:	O
concentration	O
response	O
of	O
the	O
GR3027	O
antagonism	O
of	O
200	O
nM	O
THDOC	O
enhanced	O
0	O
.	O
3	O
μM	O
GABA	O
-	O
mediated	O
current	O
response	O
with	O
the	O
α5β3γ2L	B-GP
GABAA	I-GP
receptors	I-GP
.	O

In	O
contrast	O
,	O
GR3027	O
(	O
1	O
μM	O
)	O
does	O
not	O
antagonize	O
the	O
effect	O
of	O
GABA	O
at	O
the	O
GABAA	B-GP
receptor	I-GP
(	O
Fig	O
.	O
2	O
,	O
B	O
and	O
E	O
).	O

There	O
is	O
no	O
significant	O
effect	O
of	O
GR3027	O
at	O
either	O
the	O
α1β2γ2L	B-GP
GABAA	I-GP
receptor	I-GP
[−	O
3	O
.	O
1	O
±	O
1	O
.	O
7	O
%,	O
not	O
significant	O
(	O
NS	O
)]	O
or	O
the	O
α5β3γ2L	B-GP
GABAA	I-GP
receptor	I-GP
(−	O
3	O
.	O
8	O
±	O
1	O
.	O
5	O
%,	O
NS	O
)	O
when	O
GABA	O
is	O
the	O
sole	O
activator	O
.	O

GR3027	O
dose	O
-	O
dependently	O
antagonized	O
THDOC	O
(	O
Fig	O
.	O
2	O
,	O
C	O
and	O
F	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

During	O
the	O
specific	O
conditions	O
used	O
for	O
the	O
different	O
receptors	O
,	O
IC50	O
=	O
250	O
nM	O
for	O
the	O
α1β2γ2L	B-GP
GABAA	I-GP
receptor	I-GP
and	O
350	O
nM	O
for	O
the	O
α5β3γ2L	B-GP
GABAA	I-GP
receptor	I-GP
.	O

Off	O
-	O
Target	O
Binding	O
Profile	O

At	O
10	O
μM	O
GR3027	O
did	O
not	O
show	O
binding	O
activity	O
at	O
any	O
of	O
the	O
studied	O
neurotransmitter	B-GP
-	I-GP
related	I-GP
receptors	I-GP
,	O
steroid	B-GP
receptors	I-GP
,	O
or	O
peptide	B-GP
receptors	I-GP
in	O
Table	O
1	O
.	O

GR3027	O
Restores	O
Motor	O
Coordination	O
in	O
Hyperammonemic	O
and	O
PCS	O
Rats	B-OG

Hyperammonemic	O
rats	B-OG
show	O
motor	O
incoordination	O
in	O
beam	O
walking	O
,	O
with	O
more	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
slips	O
(	O
1	O
.	O
4	O
±	O
0	O
.	O
1	O
)	O
than	O
control	O
rats	B-OG
(	O
1	O
.	O
0	O
±	O
0	O
.	O
1	O
).	O

GR3027	O
restores	O
motor	O
coordination	O
(	O
Fig	O
.	O
3A	O
)	O
at	O
3	O
mg	O
/	O
kg	O
(	O
0	O
.	O
8	O
±	O
0	O
.	O
1	O
slips	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
20	O
mg	O
/	O
kg	O
(	O
0	O
.	O
8	O
±	O
0	O
.	O
1	O
slips	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

At	O
10	O
mg	O
/	O
kg	O
GR3027	O
also	O
normalized	O
motor	O
coordination	O
(	O
1	O
.	O
0	O
±	O
0	O
.	O
2	O
slips	O
),	O
but	O
not	O
significantly	O
(	O
Fig	O
.	O
3A	O
).	O

GR3027	O
restores	O
motor	O
coordination	O
in	O
beam	O
walking	O
in	O
hyperammonemic	O
and	O
PCS	O
rats	B-OG
.	O
A	O
:	O
control	O
(	O
C	O
V	O
)	O
or	O
hyperammonemic	O
(	O
HA	O
V	O
)	O
rats	B-OG
treated	O
with	O
vehicle	O
and	O
hyperammonemic	O
rats	B-OG
treated	O
with	O
3	O
(	O
HA	O
3	O
),	O
10	O
(	O
HA	O
10	O
),	O
or	O
20	O
(	O
HA	O
20	O
)	O
mg	O
/	O
kg	O
GR3027	O
.	O
B	O
:	O
sham	O
-	O
operated	O
control	O
rats	B-OG
(	O
SM	O
V	O
)	O
or	O
PCS	O
rats	B-OG
treated	O
with	O
vehicle	O
(	O
PCS	O
V	O
)	O
and	O
PCS	O
rats	B-OG
treated	O
with	O
0	O
.	O
7	O
(	O
PCS0	O
.	O
7	O
)	O
or	O
2	O
.	O
5	O
(	O
PCS2	O
.	O
5	O
)	O
mg	O
/	O
kg	O
GR3027	O
.	O

Values	O
are	O
means	O
±	O
SE	O
for	O
number	O
of	O
rats	B-OG
indicated	O
under	O
each	O
bar	O
.	O
*	O
Different	O
from	O
control	O
or	O
sham	O
-	O
operated	O
rats	B-OG
:	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

Different	O
from	O
hyperammonemic	O
or	O
PCS	O
rats	B-OG
:	O
aP	O
<	O
0	O
.	O
05	O
,	O
aaP	O
<	O
0	O
.	O
01	O
,	O
aaaP	O
<	O
0	O
.	O
001	O
.	O

PCS	O
rats	B-OG
show	O
motor	O
incoordination	O
,	O
with	O
more	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
slips	O
(	O
1	O
.	O
2	O
±	O
0	O
.	O
1	O
)	O
than	O
control	O
rats	B-OG
(	O
0	O
.	O
71	O
±	O
0	O
.	O
07	O
).	O

GR3027	O
also	O
restores	O
motor	O
coordination	O
in	O
PCS	O
rats	B-OG
(	O
Fig	O
.	O
3B	O
),	O
reducing	O
the	O
number	O
of	O
slips	O
to	O
0	O
.	O
75	O
±	O
0	O
.	O
10	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
PCS	O
)	O
for	O
0	O
.	O
7	O
mg	O
/	O
kg	O
and	O
to	O
0	O
.	O
8	O
±	O
0	O
.	O
1	O
(	O
P	O
=	O
0	O
.	O
058	O
)	O
for	O
2	O
.	O
5	O
mg	O
/	O
kg	O
(	O
Fig	O
.	O
3B	O
).	O

GR3027	O
Restores	O
Spatial	O
Memory	O
in	O
Morris	O
Water	O
Maze	O

As	O
shown	O
in	O
Fig	O
.	O
4	O
,	O
A	O
and	O
C	O
,	O
all	O
groups	O
of	O
rats	B-OG
learned	O
the	O
position	O
of	O
the	O
hidden	O
platform	O
,	O
i	O
.	O
e	O
.,	O
decreased	O
the	O
time	O
to	O
swim	O
to	O
the	O
platform	O
over	O
the	O
3	O
days	O
with	O
practice	O
.	O

Escape	O
latencies	O
were	O
slightly	O
longer	O
in	O
hyperammonemic	O
(	O
Fig	O
.	O
4A	O
)	O
and	O
PCS	O
(	O
Fig	O
.	O
4C	O
)	O
rats	B-OG
than	O
in	O
control	O
rats	B-OG
at	O
day	O
3	O
,	O
but	O
the	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

GR3027	O
restores	O
spatial	O
memory	O
in	O
the	O
Morris	O
water	O
maze	O
in	O
hyperammonemic	O
and	O
PCS	O
rats	B-OG
.	O

Spatial	O
learning	O
and	O
memory	O
was	O
assessed	O
in	O
control	O
(	O
C	O
V	O
)	O
or	O
hyperammonemic	O
(	O
HA	O
V	O
)	O
rats	B-OG
treated	O
with	O
vehicle	O
and	O
hyperammonemic	O
rats	B-OG
treated	O
with	O
3	O
(	O
HA	O
3	O
),	O
10	O
(	O
HA	O
10	O
),	O
or	O
20	O
(	O
HA	O
20	O
)	O
mg	O
/	O
kg	O
GR3027	O
(	O
A	O
and	O
B	O
)	O
and	O
in	O
sham	O
-	O
operated	O
control	O
rats	B-OG
(	O
SM	O
V	O
)	O
or	O
PCS	O
rats	B-OG
treated	O
with	O
vehicle	O
(	O
PCS	O
V	O
)	O
and	O
PCS	O
rats	B-OG
treated	O
with	O
0	O
.	O
7	O
(	O
PCS	O
0	O
.	O
7	O
)	O
or	O
2	O
.	O
5	O
(	O
PCS	O
2	O
.	O
5	O
)	O
mg	O
/	O
kg	O
GR3027	O
(	O
C	O
and	O
D	O
).	O
A	O
and	O
C	O
:	O
escape	O
latencies	O
to	O
reach	O
the	O
platform	O
during	O
learning	O
sessions	O
.	O
B	O
and	O
D	O
:	O
time	O
spent	O
in	O
the	O
correct	O
quadrant	O
during	O
the	O
memory	O
test	O
.	O

Values	O
are	O
means	O
±	O
SE	O
for	O
the	O
number	O
of	O
rats	B-OG
indicated	O
under	O
each	O
bar	O
.	O

Different	O
from	O
control	O
or	O
sham	O
rats	B-OG
:	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

Different	O
from	O
hyperammonemic	O
or	O
PCS	O
rats	B-OG
:	O
aP	O
<	O
0	O
.	O
05	O
.	O

Spatial	O
memory	O
was	O
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
hyperammonemic	O
rats	B-OG
,	O
such	O
that	O
in	O
the	O
memory	O
test	O
they	O
remained	O
for	O
less	O
time	O
in	O
the	O
right	O
quadrant	O
(	O
30	O
±	O
2	O
%	O
of	O
time	O
)	O
than	O
control	O
rats	B-OG
(	O
39	O
±	O
2	O
%).	O

GR3027	O
restored	O
spatial	O
memory	O
in	O
the	O
Morris	O
water	O
maze	O
.	O

The	O
percentages	O
of	O
time	O
spent	O
in	O
the	O
correct	O
quadrant	O
were	O
41	O
±	O
4	O
%,	O
42	O
±	O
5	O
%,	O
and	O
38	O
±	O
3	O
%	O
for	O
3	O
,	O
10	O
,	O
and	O
20	O
mg	O
/	O
kg	O
doses	O
,	O
respectively	O
(	O
Fig	O
.	O
4B	O
).	O

Spatial	O
memory	O
was	O
also	O
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
PCS	O
rats	B-OG
.	O

In	O
the	O
memory	O
test	O
PCS	O
rats	B-OG
remained	O
for	O
less	O
time	O
in	O
the	O
right	O
quadrant	O
(	O
31	O
±	O
3	O
%	O
of	O
time	O
)	O
than	O
control	O
rats	B-OG
(	O
41	O
±	O
2	O
%).	O

GR3027	O
restored	O
spatial	O
memory	O
.	O

The	O
percentages	O
of	O
time	O
spent	O
in	O
the	O
correct	O
quadrant	O
were	O
34	O
±	O
4	O
%	O
and	O
39	O
±	O
3	O
%	O
for	O
0	O
.	O
7	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
doses	O
,	O
respectively	O
(	O
Fig	O
.	O
4D	O
).	O

GR3027	O
Restores	O
Spatial	O
Learning	O
in	O
Radial	O
Maze	O

Hyperammonemic	O
rats	B-OG
showed	O
reduced	O
spatial	O
learning	O
in	O
the	O
radial	O
maze	O
(	O
Fig	O
.	O
5A	O
).	O

The	O
number	O
of	O
working	O
errors	O
in	O
days	O
1	O
and	O
2	O
was	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
hyperammonemic	O
rats	B-OG
(	O
18	O
±	O
3	O
errors	O
)	O
than	O
in	O
control	O
rats	B-OG
(	O
11	O
±	O
1	O
.	O
5	O
errors	O
;	O
Fig	O
.	O
5B	O
).	O

Hyperammonemic	O
rats	B-OG
treated	O
with	O
GR3027	O
behaved	O
as	O
control	O
rats	B-OG
.	O

The	O
number	O
of	O
errors	O
was	O
6	O
.	O
5	O
±	O
2	O
.	O
8	O
,	O
8	O
.	O
8	O
±	O
1	O
.	O
9	O
,	O
and	O
12	O
±	O
2	O
for	O
3	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
doses	O
,	O
respectively	O
(	O
Fig	O
.	O
5B	O
).	O

GR3027	O
restores	O
spatial	O
learning	O
in	O
the	O
radial	O
maze	O
in	O
hyperammonemic	O
and	O
PCS	O
rats	B-OG
.	O

Spatial	O
learning	O
in	O
the	O
radial	O
maze	O
was	O
assessed	O
in	O
control	O
(	O
C	O
V	O
)	O
or	O
hyperammonemic	O
(	O
HA	O
V	O
)	O
rats	B-OG
treated	O
with	O
vehicle	O
or	O
(	O
for	O
hyperammonemic	O
rats	B-OG
)	O
treated	O
with	O
3	O
(	O
HA	O
3	O
),	O
10	O
(	O
HA	O
10	O
)	O
or	O
20	O
(	O
HA	O
20	O
)	O
mg	O
/	O
kg	O
GR3027	O
(	O
A	O
and	O
B	O
),	O
in	O
sham	O
-	O
operated	O
control	O
rats	B-OG
(	O
SM	O
V	O
)	O
or	O
PCS	O
rats	B-OG
treated	O
with	O
vehicle	O
(	O
PCS	O
V	O
),	O
and	O
in	O
PCS	O
rats	B-OG
treated	O
with	O
0	O
.	O
7	O
(	O
PCS	O
0	O
.	O
7	O
)	O
or	O
2	O
.	O
5	O
(	O
PCS	O
2	O
.	O
5	O
)	O
mg	O
/	O
kg	O
GR3027	O
(	O
C	O
and	O
D	O
).	O
A	O
and	O
C	O
:	O
working	O
errors	O
during	O
the	O
different	O
sessions	O
.	O
B	O
and	O
D	O
:	O
working	O
errors	O
during	O
days	O
1	O
and	O
2	O
.	O

Values	O
are	O
means	O
±	O
SE	O
for	O
the	O
number	O
of	O
rats	B-OG
indicated	O
under	O
each	O
bar	O
.	O

Different	O
from	O
control	O
or	O
sham	O
-	O
treated	O
rats	B-OG
:	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

Different	O
from	O
hyperammonemic	O
or	O
PCS	O
rats	B-OG
:	O
aP	O
<	O
0	O
.	O
05	O
,	O
aaP	O
<	O
0	O
.	O
01	O
.	O

PCS	O
rats	B-OG
also	O
showed	O
reduced	O
spatial	O
learning	O
in	O
the	O
radial	O
maze	O
(	O
Fig	O
.	O
5C	O
).	O

The	O
number	O
of	O
working	O
errors	O
in	O
days	O
1	O
–	O
2	O
(	O
Fig	O
.	O
5D	O
)	O
was	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
PCS	O
rats	B-OG
(	O
22	O
±	O
2	O
errors	O
)	O
than	O
in	O
sham	O
-	O
operated	O
rats	B-OG
(	O
10	O
±	O
2	O
errors	O
).	O

Treatment	O
of	O
PCS	O
rats	B-OG
with	O
0	O
.	O
7	O
mg	O
/	O
kg	O
GR3027	O
was	O
not	O
enough	O
to	O
improve	O
performance	O
in	O
the	O
radial	O
maze	O
(	O
23	O
±	O
2	O
errors	O
).	O

Treatment	O
with	O
2	O
.	O
5	O
mg	O
/	O
kg	O
GR3027	O
completely	O
normalized	O
performance	O
in	O
the	O
radial	O
maze	O
(	O
11	O
±	O
1	O
errors	O
,	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
PCS	O
).	O

In	O
PCS	O
rats	B-OG
,	O
therefore	O
,	O
treatment	O
with	O
0	O
.	O
7	O
mg	O
/	O
kg	O
GR3027	O
is	O
not	O
enough	O
to	O
restore	O
spatial	O
learning	O
,	O
while	O
2	O
.	O
5	O
mg	O
/	O
kg	O
restores	O
it	O
(	O
Fig	O
.	O
5D	O
).	O

This	O
indicates	O
a	O
beneficial	O
effect	O
of	O
GR3027	O
on	O
spatial	O
learning	O
.	O

GR3027	O
Partially	O
Restores	O
Circadian	O
Rhythm	O
of	O
Motor	O
Activity	O
in	O
PCS	O
Rats	B-OG

PCS	O
rats	B-OG
show	O
reduced	O
motor	O
activity	O
(	O
ambulatory	O
counts	O
)	O
during	O
the	O
night	O
(	O
active	O
phase	O
for	O
rats	B-OG
),	O
showing	O
1	O
,	O
849	O
±	O
176	O
counts	O
,	O
which	O
is	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
control	O
rats	B-OG
(	O
4	O
,	O
546	O
±	O
584	O
counts	O
).	O

GR3027	O
at	O
0	O
.	O
7	O
mg	O
/	O
kg	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
activity	O
in	O
PCS	O
rats	B-OG
to	O
2	O
,	O
652	O
±	O
275	O
counts	O
.	O

At	O
2	O
.	O
5	O
mg	O
/	O
kg	O
GR3027	O
did	O
not	O
affect	O
ambulatory	O
counts	O
(	O
2	O
,	O
235	O
±	O
170	O
counts	O
)	O
(	O
Fig	O
.	O
6B	O
).	O

GR3027	O
partially	O
restores	O
the	O
circadian	O
rhythm	O
of	O
spontaneous	O
motor	O
activity	O
.	O

Ambulatory	O
counts	O
(	O
A	O
–	O
D	O
)	O
and	O
vertical	O
activity	O
(	O
E	O
–	O
H	O
)	O
were	O
assessed	O
in	O
control	O
(	O
C	O
)	O
and	O
hyperammonemic	O
(	O
HA	O
)	O
rats	B-OG
(	O
A	O
,	O
C	O
,	O
E	O
,	O
G	O
)	O
treated	O
with	O
vehicle	O
(	O
V	O
)	O
or	O
with	O
20	O
mg	O
/	O
kg	O
GR3027	O
and	O
in	O
sham	O
-	O
operated	O
control	O
rats	B-OG
(	O
SMV	O
)	O
or	O
PCS	O
rats	B-OG
(	O
B	O
,	O
D	O
,	O
F	O
,	O
H	O
)	O
treated	O
with	O
vehicle	O
(	O
PCSV	O
)	O
or	O
with	O
0	O
.	O
7	O
(	O
PCS0	O
.	O
7	O
)	O
or	O
2	O
.	O
5	O
(	O
PCS2	O
.	O
5	O
)	O
mg	O
/	O
kg	O
GR3027	O
.	O

Motor	O
activity	O
during	O
night	O
and	O
day	O
is	O
shown	O
in	O
A	O
,	O
B	O
,	O
E	O
and	O
F	O
and	O
the	O
ratios	O
of	O
activity	O
night	O
to	O
day	O
in	O
C	O
,	O
D	O
,	O
G	O
,	O
and	O
H	O
.	O

Values	O
are	O
means	O
±	O
SE	O
of	O
8	O
rats	B-OG
per	O
group	O
.	O

Different	O
from	O
hyperammonemic	O
or	O
PCS	O
rats	B-OG
:	O
aP	O
<	O
0	O
.	O
05	O
,	O
aaP	O
<	O
0	O
.	O
01	O
.	O

Different	O
from	O
control	O
/	O
sham	O
:	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

The	O
night	O
-	O
to	O
-	O
day	O
ratio	O
of	O
ambulatory	O
activity	O
was	O
reduced	O
in	O
PCS	O
rats	B-OG
,	O
indicating	O
altered	O
circadian	O
rhythm	O
(	O
Fig	O
.	O
6D	O
).	O

This	O
ratio	O
was	O
3	O
.	O
3	O
±	O
0	O
.	O
4	O
in	O
control	O
rats	B-OG
and	O
was	O
reduced	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
PCS	O
rats	B-OG
to	O
0	O
.	O
8	O
±	O
0	O
.	O
16	O
.	O

GR3027	O
improved	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
night	O
-	O
to	O
-	O
day	O
ratio	O
of	O
activity	O
,	O
reaching	O
1	O
.	O
7	O
±	O
0	O
.	O
2	O
and	O
1	O
.	O
6	O
±	O
0	O
.	O
3	O
for	O
0	O
.	O
7	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

This	O
indicates	O
partial	O
restoration	O
of	O
circadian	O
rhythm	O
of	O
activity	O
.	O

Hyperammonemic	O
rats	B-OG
also	O
showed	O
reduced	O
ambulatory	O
activity	O
during	O
the	O
night	O
and	O
night	O
-	O
to	O
-	O
day	O
ratio	O
of	O
activity	O
compared	O
with	O
control	O
rats	B-OG
(	O
Fig	O
.	O
6	O
,	O
A	O
and	O
C	O
).	O

GR3027	O
at	O
20	O
mg	O
/	O
kg	O
showed	O
a	O
tendency	O
to	O
slightly	O
increase	O
the	O
activity	O
and	O
the	O
ratio	O
,	O
but	O
the	O
effect	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

GR3027	O
Normalizes	O
Vertical	O
Activity	O
During	O
the	O
Day	O
and	O
Partially	O
Restores	O
Its	O
Circadian	O
Rhythm	O

PCS	O
rats	B-OG
showed	O
reduced	O
vertical	O
activity	O
during	O
the	O
night	O
(	O
active	O
phase	O
),	O
showing	O
561	O
±	O
108	O
counts	O
,	O
which	O
is	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
control	O
rats	B-OG
(	O
1	O
,	O
228	O
±	O
138	O
counts	O
).	O

GR3027	O
at	O
0	O
.	O
7	O
mg	O
/	O
kg	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
did	O
not	O
affect	O
nocturnal	O
vertical	O
activity	O
(	O
664	O
±	O
121	O
and	O
695	O
±	O
185	O
counts	O
,	O
respectively	O
)	O
(	O
Fig	O
.	O
6F	O
).	O

In	O
contrast	O
,	O
PCS	O
rats	B-OG
show	O
increased	O
vertical	O
activity	O
during	O
the	O
day	O
,	O
showing	O
682	O
±	O
114	O
counts	O
,	O
which	O
is	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
control	O
rats	B-OG
(	O
391	O
±	O
64	O
counts	O
).	O

GR3027	O
at	O
0	O
.	O
7	O
mg	O
/	O
kg	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
completely	O
normalized	O
vertical	O
activity	O
during	O
the	O
day	O
,	O
reaching	O
339	O
±	O
47	O
and	O
424	O
±	O
44	O
counts	O
,	O
respectively	O
(	O
Fig	O
.	O
6F	O
).	O

The	O
night	O
-	O
to	O
-	O
day	O
ratio	O
of	O
vertical	O
activity	O
is	O
reduced	O
in	O
PCS	O
rats	B-OG
,	O
indicating	O
altered	O
circadian	O
rhythm	O
(	O
Fig	O
.	O
6H	O
).	O

This	O
ratio	O
is	O
3	O
.	O
7	O
±	O
0	O
.	O
6	O
in	O
control	O
rats	B-OG
and	O
is	O
reduced	O
in	O
PCS	O
rats	B-OG
to	O
0	O
.	O
8	O
±	O
0	O
.	O
01	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

GR3027	O
improved	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
the	O
night	O
-	O
to	O
-	O
day	O
ratio	O
of	O
activity	O
,	O
reaching	O
2	O
.	O
1	O
±	O
0	O
.	O
4	O
and	O
1	O
.	O
9	O
±	O
0	O
.	O
6	O
for	O
0	O
.	O
7	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
,	O
respectively	O
(	O
Fig	O
.	O
6H	O
).	O

This	O
indicates	O
partial	O
restoration	O
of	O
circadian	O
rhythm	O
of	O
vertical	O
activity	O
.	O

Hyperammonemic	O
rats	B-OG
also	O
showed	O
reduced	O
vertical	O
activity	O
during	O
the	O
night	O
and	O
night	O
-	O
to	O
-	O
day	O
ratio	O
of	O
activity	O
compared	O
with	O
control	O
rats	B-OG
(	O
Fig	O
.	O
6	O
,	O
E	O
and	O
G	O
).	O

GR3027	O
at	O
20	O
mg	O
/	O
kg	O
did	O
not	O
affect	O
the	O
activity	O
or	O
the	O
ratio	O
.	O

GR3027	O
Does	O
Not	O
Affect	O
Ammonia	O
Levels	O

Blood	O
ammonia	O
levels	O
were	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
hyperammonemic	O
rats	B-OG
(	O
167	O
±	O
16	O
μM	O
)	O
compared	O
with	O
control	O
rats	B-OG
(	O
47	O
±	O
3	O
μM	O
).	O

GR3027	O
did	O
not	O
affect	O
ammonia	O
levels	O
in	O
hyperammonemic	O
rats	B-OG
(	O
139	O
±	O
14	O
μM	O
).	O

Blood	O
ammonia	O
levels	O
were	O
also	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
PCS	O
rats	B-OG
(	O
411	O
±	O
39	O
μM	O
)	O
compared	O
with	O
sham	O
-	O
operated	O
rats	B-OG
(	O
51	O
±	O
13	O
μM	O
).	O

GR3027	O
did	O
not	O
affect	O
blood	O
ammonia	O
,	O
which	O
remained	O
at	O
380	O
±	O
22	O
and	O
348	O
±	O
75	O
μM	O
in	O
PCS	O
rats	B-OG
treated	O
with	O
0	O
.	O
7	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
GR3027	O
,	O
respectively	O
.	O

GR3027	O
Exposure	O
in	O
Hyperammonemic	O
and	O
PCS	O
Rats	B-OG

In	O
hyperammonemic	O
rats	B-OG
the	O
once	O
-	O
daily	O
administration	O
of	O
GR3027	O
at	O
3	O
,	O
10	O
,	O
and	O
20	O
mg	O
/	O
kg	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
exposure	O
in	O
plasma	O
and	O
brain	O
.	O

At	O
the	O
time	O
of	O
behavioral	O
testing	O
the	O
total	O
concentrations	O
of	O
GR3027	O
in	O
plasma	O
were	O
0	O
.	O
34	O
±	O
0	O
.	O
03	O
,	O
1	O
.	O
08	O
±	O
0	O
.	O
11	O
,	O
and	O
1	O
.	O
95	O
±	O
0	O
.	O
61	O
μM	O
,	O
respectively	O
,	O
and	O
in	O
the	O
brain	O
tissue	O
the	O
unbound	O
concentrations	O
of	O
GR3027	O
were	O
6	O
.	O
1	O
±	O
1	O
.	O
4	O
,	O
11	O
.	O
6	O
±	O
1	O
.	O
4	O
,	O
and	O
23	O
±	O
5	O
nmol	O
/	O
kg	O
,	O
respectively	O
(	O
Fig	O
.	O
7	O
).	O

GR3027	O
exposures	O
in	O
plasma	O
and	O
in	O
the	O
brain	O
at	O
time	O
for	O
behavioral	O
testing	O
.	O
A	O
and	O
B	O
:	O
in	O
hyperammonemic	O
(	O
A	O
)	O
and	O
PCS	O
(	O
B	O
)	O
rats	B-OG
,	O
the	O
total	O
plasma	O
concentrations	O
of	O
GR3027	O
are	O
shown	O
in	O
μM	O
.	O
C	O
and	O
D	O
:	O
in	O
hyperammonemic	O
(	O
C	O
)	O
and	O
PCS	O
(	O
D	O
)	O
rats	B-OG
,	O
the	O
unbound	O
brain	O
concentrations	O
of	O
GR3027	O
are	O
shown	O
in	O
nmol	O
/	O
kg	O
.	O

Note	O
the	O
similar	O
exposures	O
in	O
the	O
different	O
rat	B-OG
models	O
with	O
the	O
doses	O
used	O
,	O
in	O
hyperammonemic	O
rats	B-OG
3	O
,	O
10	O
,	O
and	O
20	O
mg	O
·	O
kg	O
−	O
1	O
·	O
day	O
−	O
1	O
and	O
in	O
rats	B-OG
with	O
PCS	O
0	O
.	O
7	O
and	O
2	O
.	O
5	O
mg	O
·	O
kg	O
−	O
1	O
·	O
day	O
−	O
1	O
.	O

Data	O
are	O
from	O
the	O
end	O
of	O
the	O
study	O
,	O
i	O
.	O
e	O
.,	O
after	O
9	O
wk	O
of	O
daily	O
treatments	O
with	O
GR3027	O
in	O
sesame	B-OG
oil	O
given	O
subcutaneously	O
once	O
daily	O
.	O

GAMSA	O
,	O
GABAA	B-GP
receptor	I-GP
-	O
modulating	O
steroid	O
antagonist	O
.	O

In	O
PCS	O
rats	B-OG
the	O
exposures	O
were	O
also	O
dose	O
dependent	O
,	O
and	O
with	O
the	O
lower	O
doses	O
used	O
in	O
these	O
rats	B-OG
,	O
0	O
.	O
7	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
,	O
the	O
exposures	O
were	O
very	O
similar	O
to	O
those	O
in	O
the	O
hyperammonemic	O
rats	B-OG
.	O

At	O
the	O
time	O
of	O
behavioral	O
testing	O
total	O
concentrations	O
in	O
plasma	O
were	O
0	O
.	O
48	O
±	O
0	O
.	O
09	O
and	O
1	O
.	O
64	O
±	O
0	O
.	O
30	O
μM	O
,	O
at	O
0	O
.	O
7	O
and	O
2	O
.	O
5	O
mg	O
·	O
kg	O
−	O
1	O
·	O
day	O
−	O
1	O
,	O
respectively	O
,	O
and	O
unbound	O
concentrations	O
in	O
the	O
brain	O
were	O
6	O
.	O
18	O
±	O
0	O
.	O
97	O
and	O
17	O
±	O
2	O
nmol	O
/	O
kg	O
,	O
respectively	O
(	O
Fig	O
.	O
7	O
).	O

These	O
data	O
clearly	O
show	O
that	O
alteration	O
of	O
liver	O
function	O
or	O
portosystemic	O
shunts	O
affects	O
the	O
systemic	O
dose	O
of	O
the	O
drug	O
to	O
be	O
used	O
to	O
reach	O
the	O
levels	O
obtained	O
in	O
the	O
absence	O
of	O
liver	B-DS
failure	I-DS
.	O

The	O
data	O
in	O
Fig	O
.	O
7	O
show	O
that	O
the	O
levels	O
of	O
GR3027	O
in	O
plasma	O
and	O
brain	O
of	O
PCS	O
rats	B-OG
injected	O
with	O
0	O
.	O
7	O
mg	O
/	O
kg	O
are	O
similar	O
to	O
those	O
reached	O
in	O
hyperammonemic	O
rats	B-OG
injected	O
with	O
3	O
mg	O
/	O
kg	O
.	O

For	O
PCS	O
rats	B-OG
injected	O
with	O
2	O
.	O
5	O
mg	O
/	O
kg	O
,	O
the	O
levels	O
reached	O
in	O
plasma	O
are	O
intermediate	O
between	O
those	O
reached	O
in	O
hyperammonemic	O
rats	B-OG
injected	O
with	O
10	O
and	O
20	O
mg	O
/	O
kg	O
.	O

This	O
indicates	O
that	O
doses	O
in	O
the	O
range	O
between	O
four	O
-	O
and	O
eightfold	O
lower	O
are	O
required	O
in	O
PCS	O
rats	B-OG
to	O
reach	O
the	O
same	O
plasma	O
and	O
brain	O
GR3027	O
levels	O
as	O
in	O
hyperammonemic	O
rats	B-OG
without	O
liver	B-DS
failure	I-DS
.	O

DISCUSSION	O

We	O
show	O
for	O
the	O
first	O
time	O
that	O
a	O
selective	O
inhibitor	O
of	O
positive	O
neurosteroid	O
modulation	O
of	O
the	O
GABAA	B-GP
receptor	I-GP
restores	O
motor	O
coordination	O
and	O
spatial	O
learning	O
and	O
memory	O
in	O
rats	B-OG
with	O
HE	B-DS
.	O

GR3027	O
also	O
partially	O
restores	O
the	O
circadian	O
rhythm	O
of	O
motor	O
activity	O
.	O

Similar	O
beneficial	O
effects	O
of	O
GR3027	O
would	O
be	O
expected	O
in	O
the	O
motor	O
coordination	O
and	O
cognitive	O
function	O
of	O
patients	O
with	O
HE	B-DS
.	O

Restoration	O
of	O
motor	O
coordination	O
by	O
GR3027	O
would	O
be	O
due	O
to	O
a	O
reduction	O
of	O
the	O
GABAergic	O
tone	O
in	O
cerebellum	O
.	O

Increased	O
GABAergic	O
tone	O
in	O
cerebellum	O
induces	O
motor	O
incoordination	O
,	O
and	O
the	O
extracellular	O
GABA	O
concentration	O
in	O
cerebellum	O
correlates	O
with	O
motor	O
incoordination	O
in	O
rats	B-OG
(	O
9	O
).	O

In	O
hyperammonemic	O
rats	B-OG
,	O
extracellular	O
GABA	O
in	O
cerebellum	O
correlates	O
with	O
motor	O
incoordination	O
and	O
reduction	O
of	O
GABA	O
in	O
cerebellum	O
by	O
pregnenolone	O
sulfate	O
restores	O
motor	O
coordination	O
(	O
17	O
).	O

Improved	O
motor	O
coordination	O
is	O
also	O
achieved	O
with	O
the	O
novel	O
compound	O
GR3027	O
,	O
which	O
antagonizes	O
the	O
neurosteroids	O
that	O
enhance	O
activation	O
of	O
GABAA	B-GP
receptors	I-GP
.	O

We	O
show	O
that	O
GR3027	O
restores	O
spatial	O
learning	O
and	O
memory	O
in	O
the	O
radial	O
and	O
Morris	O
water	O
mazes	O
in	O
hyperammonemic	O
and	O
PCS	O
rats	B-OG
.	O

Impairment	O
of	O
learning	O
and	O
memory	O
would	O
be	O
due	O
to	O
enhanced	O
GABAergic	O
tone	O
in	O
the	O
hippocampus	O
,	O
and	O
restoration	O
by	O
GR3027	O
would	O
be	O
due	O
to	O
reduction	O
of	O
the	O
neurosteroid	O
-	O
induced	O
activation	O
of	O
GABAA	B-GP
receptors	I-GP
.	O

Overactivation	O
of	O
GABAA	B-GP
receptors	I-GP
in	O
the	O
hippocampus	O
impairs	O
spatial	O
learning	O
and	O
memory	O
in	O
different	O
situations	O
(	O
24	O
,	O
33	O
,	O
39	O
,	O
41	O
).	O

Reducing	O
the	O
GABAergic	O
tone	O
improves	O
spatial	O
learning	O
,	O
for	O
example	O
,	O
in	O
models	O
for	O
Down	B-DS
syndrome	I-DS
,	O
circadian	B-DS
arrhythmia	I-DS
,	O
or	O
alcohol	O
ingestion	O
(	O
26	O
,	O
31	O
).	O

Enhanced	O
activation	O
of	O
α5	O
-	O
containing	O
GABAA	B-GP
receptors	I-GP
during	O
inflammation	O
(	O
41	O
)	O
or	O
by	O
etomidate	O
(	O
25	O
)	O
impairs	O
memory	O
,	O
and	O
α5	O
-	O
selective	O
inverse	O
agonists	O
function	O
as	O
cognitive	O
enhancers	O
in	O
animal	B-OG
models	O
(	O
32	O
).	O

Both	O
α1	O
-	O
subunit	O
-	O
and	O
α5	O
-	O
subunit	O
-	O
containing	O
GABAA	B-GP
receptors	I-GP
are	O
involved	O
in	O
benzodiazepine	O
-	O
induced	O
decreased	O
learning	O
and	O
memory	O
in	O
the	O
Morris	O
water	O
maze	O
(	O
33	O
).	O

Thus	O
GR3027	O
antagonism	O
of	O
neurosteroid	O
enhancement	O
of	O
both	O
α1	O
-	O
and	O
α5	O
-	O
containing	O
hippocampal	O
GABAA	B-GP
receptors	I-GP
might	O
be	O
involved	O
in	O
restoration	O
of	O
learning	O
and	O
memory	O
in	O
HE	B-DS
.	O

This	O
agrees	O
with	O
our	O
previous	O
report	O
showing	O
that	O
impairment	O
of	O
spatial	O
learning	O
in	O
the	O
Morris	O
water	O
maze	O
by	O
acute	O
GABAA	B-GP
receptor	I-GP
activation	O
by	O
neurosteroid	O
treatment	O
is	O
improved	O
by	O
the	O
neurosteroid	O
antagonist	O
UC1011	O
(	O
39	O
).	O

The	O
results	O
reported	O
show	O
that	O
in	O
PCS	O
rats	B-OG
treatment	O
with	O
0	O
.	O
7	O
mg	O
/	O
kg	O
GR3027	O
is	O
enough	O
to	O
restore	O
motor	O
coordination	O
(	O
Fig	O
.	O
3B	O
)	O
but	O
not	O
spatial	O
learning	O
in	O
the	O
radial	O
maze	O
(	O
Fig	O
.	O
5D	O
).	O

This	O
indicates	O
that	O
in	O
PCS	O
rats	B-OG
different	O
doses	O
of	O
GR3027	O
are	O
required	O
to	O
restore	O
different	O
types	O
of	O
neurological	O
impairments	O
.	O

One	O
reason	O
for	O
this	O
could	O
be	O
that	O
motor	O
coordination	O
is	O
mainly	O
modulated	O
in	O
the	O
cerebellum	O
while	O
spatial	O
learning	O
is	O
mainly	O
modulated	O
in	O
the	O
hippocampus	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
GR3027	O
is	O
to	O
antagonize	O
the	O
neurosteroid	O
enhancement	O
(	O
allopregnanolone	O
and	O
THDOC	O
)	O
of	O
GABAA	B-GP
receptor	I-GP
activity	O
.	O

As	O
the	O
levels	O
of	O
these	O
neurosteroids	O
and	O
the	O
expression	O
of	O
GABAA	B-GP
receptor	I-GP
subtypes	O
are	O
different	O
in	O
different	O
brain	O
areas	O
(	O
12	O
,	O
45	O
),	O
different	O
doses	O
of	O
GR3027	O
would	O
be	O
needed	O
for	O
modulation	O
of	O
each	O
specific	O
behavior	O
.	O

GR3027	O
also	O
partially	O
improves	O
the	O
alterations	O
in	O
circadian	O
rhythms	O
of	O
activity	O
in	O
rats	B-OG
with	O
HE	B-DS
.	O

The	O
mechanisms	O
underlying	O
these	O
alterations	O
are	O
not	O
well	O
known	O
,	O
and	O
it	O
would	O
be	O
speculative	O
to	O
discuss	O
the	O
mechanisms	O
underlying	O
the	O
beneficial	O
effects	O
of	O
GR3027	O
.	O

Nevertheless	O
,	O
altered	O
circadian	O
rhythms	O
of	O
activity	O
are	O
associated	O
with	O
altered	O
sleep	O
in	O
PCS	O
rats	B-OG
(	O
23	O
),	O
which	O
reproduce	O
the	O
sleep	O
alterations	O
of	O
cirrhotic	O
patients	O
,	O
who	O
cannot	O
sleep	O
well	O
during	O
the	O
night	O
and	O
show	O
sleepiness	O
during	O
the	O
day	O
.	O

The	O
beneficial	O
effect	O
of	O
GR3027	O
on	O
circadian	O
rhythms	O
of	O
activity	O
suggests	O
that	O
it	O
could	O
also	O
improve	O
sleep	O
in	O
cirrhotic	O
patients	O
.	O

GR3027	O
is	O
a	O
GABAA	B-GP
receptor	I-GP
-	O
modulating	O
steroid	O
antagonist	O
,	O
GAMSA	O
,	O
that	O
is	O
,	O
a	O
compound	O
that	O
antagonizes	O
the	O
neurosteroid	O
enhancement	O
of	O
GABAA	B-GP
receptor	I-GP
activation	O
but	O
is	O
without	O
effect	O
when	O
activating	O
steroids	O
as	O
allopregnanolone	O
and	O
THDOC	O
are	O
not	O
present	O
.	O

Thus	O
GR3027	O
does	O
not	O
antagonize	O
the	O
effect	O
of	O
GABA	O
,	O
which	O
is	O
preferable	O
from	O
a	O
safety	O
perspective	O
as	O
there	O
will	O
be	O
no	O
risk	O
for	O
seizure	O
induction	O
by	O
GR3027	O
.	O

This	O
is	O
different	O
from	O
other	O
GABAA	B-GP
receptor	I-GP
active	O
substances	O
with	O
beneficial	O
effects	O
on	O
cognition	O
in	O
HE	B-DS
models	O
(	O
12	O
,	O
17	O
),	O
as	O
both	O
pregnenolone	O
sulfate	O
and	O
bicuculline	O
block	O
the	O
effect	O
of	O
GABA	O
at	O
the	O
receptor	O
.	O

Moreover	O
,	O
pregnenolone	O
sulfate	O
does	O
not	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
was	O
administered	O
intracerebrally	O
(	O
17	O
),	O
while	O
GR3027	O
affords	O
beneficial	O
effects	O
by	O
peripheral	O
administration	O
.	O

The	O
action	O
of	O
GR3027	O
is	O
also	O
different	O
from	O
that	O
of	O
flumazenil	O
,	O
which	O
transiently	O
improves	O
mental	O
status	O
in	O
some	O
HE	B-DS
patients	O
(	O
20	O
).	O

Flumazenil	O
does	O
not	O
inhibit	O
the	O
effect	O
of	O
allopregnanolone	O
at	O
the	O
GABAA	B-GP
receptor	I-GP
but	O
effectively	O
antagonizes	O
benzodiazepine	O
effects	O
(	O
2	O
).	O

The	O
main	O
advantage	O
of	O
GR3027	O
over	O
currently	O
used	O
drugs	O
for	O
treating	O
HE	B-DS
in	O
patients	O
is	O
that	O
GR3027	O
acts	O
on	O
a	O
brain	O
target	O
,	O
by	O
modulating	O
GABAA	B-GP
receptor	I-GP
activation	O
.	O

Therefore	O
GR3027	O
may	O
normalize	O
GABAergic	O
neurotransmission	O
and	O
restore	O
neurological	O
functions	O
altered	O
because	O
of	O
overactivation	O
of	O
GABAA	B-GP
receptors	I-GP
,	O
even	O
if	O
hyperammonemia	B-DS
and	O
inflammation	O
associated	O
with	O
chronic	B-DS
liver	I-DS
disease	I-DS
remain	O
present	O
.	O

Thus	O
GR3027	O
may	O
afford	O
a	O
more	O
complete	O
normalization	O
of	O
motor	O
coordination	O
and	O
cognitive	O
function	O
by	O
acting	O
on	O
a	O
step	O
that	O
mediates	O
the	O
effects	O
of	O
hyperammonemia	B-DS
and	O
inflammation	O
on	O
neurological	O
functions	O
.	O

GRANTS	O

This	O
study	O
was	O
financed	O
by	O
Umecrine	O
Cognition	O
AB	O
.	O

DISCLOSURES	O

This	O
study	O
was	O
financed	O
by	O
Umecrine	O
Cognition	O
AB	O
.	O

All	O
authors	O
therefore	O
have	O
this	O
conflict	O
of	O
interest	O
.	O

AUTHOR	O
CONTRIBUTIONS	O

Author	O
contributions	O
:	O
M	O
.	O
J	O
.,	O
M	O
.	O
D	O
.,	O
T	O
.	O
B	O
.,	O
and	O
V	O
.	O
F	O
.	O
conception	O
and	O
design	O
of	O
research	O
;	O
M	O
.	O
J	O
.,	O
M	O
.	O
D	O
.,	O
and	O
V	O
.	O
F	O
.	O
interpreted	O
results	O
of	O
experiments	O
;	O
M	O
.	O
J	O
.,	O
M	O
.	O
D	O
.,	O
T	O
.	O
B	O
.,	O
and	O
V	O
.	O
F	O
.	O
edited	O
and	O
revised	O
manuscript	O
;	O
A	O
.	O
A	O
.,	O
M	O
.	O
L	O
.,	O
C	O
.	O
M	O
.,	O
J	O
.	O
S	O
.,	O
E	O
.	O
M	O
.,	O
and	O
G	O
.	O
R	O
.	O
performed	O
experiments	O
;	O
A	O
.	O
A	O
.,	O
M	O
.	O
L	O
.,	O
C	O
.	O
M	O
.,	O
J	O
.	O
S	O
.,	O
E	O
.	O
M	O
.,	O
G	O
.	O
R	O
.,	O
and	O
V	O
.	O
F	O
.	O
analyzed	O
data	O
;	O
A	O
.	O
A	O
.	O
and	O
M	O
.	O
L	O
.	O
prepared	O
figures	O
;	O
M	O
.	O
D	O
.,	O
T	O
.	O
B	O
.,	O
and	O
V	O
.	O
F	O
.	O
approved	O
final	O
version	O
of	O
manuscript	O
;	O
V	O
.	O
F	O
.	O
drafted	O
manuscript	O
.	O

